TIDMMHC

RNS Number : 2848N

MyHealthChecked PLC

29 September 2021

MyHealthChecked Plc

("MyHealthChecked", "MHC" or the "Company")

Half-year Report

MyHealthChecked Plc, the consumer home-testing healthcare company, announces its unaudited half year report for the six months ended 30 June 2021, a period of considerable growth driven by a dramatic ramp-up in COVID-19 PCR testing service revenues.

The Company also provides an update on further strong trading in Q3 (revenues of at least GBP8.5m, adjusted EBITDA* of no less than GBP1.4m, and cash generative for the first time) as well as a statement on trading outlook for the full year.

Commercial Highlights

-- Signed two commercial agreements with Boots UK Limited for supply of COVID-19 PCR test kits and associated laboratory services

-- Signed a commercial agreement with AAH Pharmaceuticals Limited (Lloyds Pharmacy) for supply of COVID-19 PCR test kits and associated laboratory services

-- Acquisition and integration of Nell Health Limited, a provider of genetic testing and personalized nutrition consultancy

   --    Accreditation by UKAS of ISO 15189 stage 3 

Financial Position

   --    Revenue of GBP3,274,145 during the period (H1 2020: GBP12,707) 
   --    Adjusted EBITDA* loss of -GBP199,670 (H1 2020 : loss of -GBP1,171,359) 
   --    Completion of share placing of GBP3.4m (before expenses) at 1.75p per share in Feb 2021 
   --    Cash balance at the period end was GBP2,214,496 (H1 2020 : GBP1,351,745) 

*adjusted EBITDA is Operating profit adjusted for depreciation, amortisation and share based payments

Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said: "I'm incredibly proud of the progress the Company has made during the last six months. We have secured commercial contracts with both of the UK's top pharmacy retailers, ending H1 2021 with a strong cash position and significantly increased revenues compared to H1 2020.

"We continue to grow as an organisation and with our talented team, which has been enhanced through the acquisition of Nell Health, I look forward to seeing the Company go from strength to strength in H2. While COVID-19 has been the predominant focus for us during the last 12 months, I am excited to continue development of our extended product pipline to market and continue to build MyHealthChecked's reputation for high-quality products and services."

 
 MyHealthChecked plc                                                               www.myhealthchecked.com 
 P enny McCormick , Chief Executive                                                        via Walbrook PR 
  Officer 
 Gareth Davies, Chief Financial and 
  Operations Officer 
 
 SPARK Advisory Partners Limited (NOMAD)                                          Tel: +44 (0)20 3368 3550 
 Neil Baldwin 
 
 Oberon Capital Ltd (Broker)                                                      Tel: +44 (0)203 179 5344 
 Mike Seabrook                                                          mikeseabrook@oberoninvestments.com 
 
 Walbrook PR Ltd (Media &                    Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com 
  IR) 
 Paul McManus / Alice Woodings                                       Mob: +44(0)7980 541 893 / +44 (0)7407 
                                                                                                   804 654 
 
 

About MyHealthChecked PLC ( www.myhealthcheckedplc.com )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online, and would be viable for over the counter purchase.

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

Chairman & CEO Joint Statement

Overview

The Company reports a strong performance this year, having made significant progress since the launch of its COVID-19 PCR testing service in December 2020.

Trading for the year began to ramp up in Q2 following the signing of a contract with Boots UK Limited, the UK's largest pharmacy retailer, and launch on 17 April, followed by a second contract and the launch of the Day 2 and 8 COVID-19 testing service on 7 May. Subsequently a contract has been signed with Lloyds Pharmacy, the UK's second largest pharmacy retailer for supply of COVID-19 PCR test kits and associated laboratory services .

The Board is confident that trading for the full year will deliver performance in H2 considerably higher than H1, due to the continued high demand through the peak holiday period during the summer months in Q3. Beyond the period, MHC is well placed with its established customer base to continue to supply a good proportion of the COVID-19 testing market, whilst factoring recent Government changes to COVID-19 testing requirements for travellers to the UK announced in mid-September 2021.

The Board expects that revenue generated in Q3 to be at least GBP8.5m and deliver an adjusted EBITDA profit for the quarter of no less than GBP1.4m. The business will be cash generative in the quarter and expects cash balances to be at least GBP3.4m at the end of Q3.

However it is too early to fully assess the effect of the recent changes to the Government COVID-19 testing requirements as we move into the quieter fourth quarter of this financial year, therefore given this uncertainty the Company is not making a forecast for either revenue or profitability for Q4 at this time.

We have made progress in the following key areas in 2021:

Commercial Relationships

During the past 6 months we have secured contracts with both of the UK's top pharmacy retailers, Boots and Lloyds. Following robust due diligence processes and collaboration for successful on-time launches, we have worked to build supportive relationships with both of our primary customers. Whilst the relationships are still in their early stages, we are building upon our reputation within these key organisations daily and are well positioned to collaborate further both inside and out of the COVID-19 testing arena.

Outside of retail, we have worked with several smaller accounts to deliver a first class COVID-19 testing service. This has included partners within the independent pharmacy, travel and media production industries and academia.

Personalised Wellness Tests

We completed a second acquisition in July 2021 - Nell Health Limited - which brought to us a broader range of validated saliva-based DNA tests. Our pipeline is defined and is currently in development. We will accelerate our developments at every opportunity, ensuring our talent and operation is sourced to deliver to the most efficient timeline.

Technology

Following the acquisition of Nell Health Limited, MHC has the ability to create innovative technology in-house, that is secure, adaptable, and robust for future product and service developments. In 2021 we have developed a new scalable platform customer facing e-commerce platform and Laboratory Information Management System that will house our future portfolio, and we transitioned our core business across to this.

Capital Expenditure on facilities

We have invested in building a UKAS approved ISO-15189 facility in Manchester, offering COVID-19 testing services to customers including same day turnaround.

Cash position

Following the completion of an equity raise in February 2021, we are pleased to report a GBP2.21m cash position at 30 June 2021 and report no material borrowings. These funds will be reinvested in 2021 into the talent and pipeline of the organisation, priming us for new market launches in 2022.

Strategy in 2022

There is a likelihood that due to the nature of the COVID-19 virus, private testing could continue into 2022, and whilst the Company will continue to deliver to its retail and consumer market, it is firmly focused on re-investing earnings generated in 2021 into its new product pipeline of at-home wellness tests, and long-term growth drivers including a Smartphone App, and wellness-enhancing customer education. Building upon the foundations laid this year and the reputation that has been built in the consumer and retail testing spaces, investment in the MyHealthChecked brand and marketing will aim to further maximise reach through the creation of an ownable, identifiable and desirable consumer brand.

Whilst delivering our new product pipeline development and building digital healthcare-centric technology that is scalable, we will continue to operate efficiently due to the unpredictability of the COVID-19 space, whilst maximising future value through our investment in 2021 earnings into long-term growth drivers including technology, talent, and commercialisation.

Our aims in 2022 are to:

-- Launch an initial portfolio of at home wellness tests, providing indications around weight management, vitamin deficiency, food intolerances, heart health and blood glucose

-- Develop app technology that provides actionable health and nutritional guidance that is tailored to the customer

   --    Execute a business development strategy across direct to consumer, retail, and B2B channels 

-- Continue to build a reputation in the COVID-19 testing space, providing a high-quality product and service

   --    Bring additional talent into the organisation to deliver on our ambitious plans 

-- Continue to explore third party technology that may enhance the customer journey and value of our products, and that can be integrated by our in-house talent

-- Identify and assess complementary earnings-enhancing partnerships with organizations that demonstrate the addition of key strategic value to our core business

We would like to thank our team, Board members and investors for their ongoing support of MyHealthChecked through this period of 2021. Whilst we have transitioned the organisation, we are delighted to be able to share a very positive set of results, and demonstrate our commitment to building a successful and secure business to the loyal team and investor base through this new and exciting growth phase of the organisation.

 
 Adam Reynolds           Penny McCormick 
 Chairman        Chief Executive Officer 
 

29 September 2021

Consolidated statement of comprehensive income

For the 6 months ended 30 June 2021

 
                                                                              Audited 
                                              Unaudited       Unaudited     12 months 
                                            6 months to     6 months to            to 
                                                                          31 December 
                                           30 June 2021    30 June 2020          2020 
                                   Notes            GBP             GBP           GBP 
--------------------------------  ------  -------------  --------------  ------------ 
 
 Revenue                               3      3,274,145          12,707        49,480 
 Cost of sales                              (2,174,271)       (174,067)     (689,782) 
 
 Gross profit / (loss)                        1,099,874       (161,360)     (640,302) 
 
 Other administrative expenses              (1,299,544)     (1,009,999)   (2,857,308) 
  Depreciation and amortisation                (60,677)       (100,989)     (157,169) 
 Share-based payments                           (6,593)        (74,553)     (103,290) 
--------------------------------  ------  -------------  --------------  ------------ 
 Administrative expenses                    (1,366,814)     (1,185,541)   (3,117,767) 
--------------------------------  ------  -------------  --------------  ------------ 
 Operating loss                               (266,940)     (1,346,901)   (3,758,069) 
 
 Finance expenses                               (1,782)         (1,981)       (4,558) 
--------------------------------  ------  -------------  --------------  ------------ 
 Loss before income tax                       (268,722)     (1,348,882)   (3,762,627) 
 
 Tax credit                            5              -               -             - 
 
 Loss for the period                          (268,722)     (1,348,882)   (3,762,627) 
--------------------------------  ------  -------------  --------------  ------------ 
 
 Attributable to owners 
  of the parent:                              (268,722)     (1,348,882)   (3,762,627) 
 
 Loss per ordinary share 
  - basic and diluted (pence)          4         (0.04)          (0.39)        (0.89) 
 

Consolidated statement of financial position

As at 30 June 2021

 
                                      Unaudited                        Audited 
                                        30 June       Unaudited    31 December 
                                           2021    30 June 2020           2020 
                                            GBP             GBP            GBP 
-------------------------------   -------------  --------------  ------------- 
 Non-current assets 
 Property, plant and equipment          151,774          70,185         55,517 
 Intangible assets                      503,389         742,071        616,560 
 Total non-current assets               655,163         812,256        672,077 
--------------------------------  -------------  --------------  ------------- 
 
 Current assets 
 Inventories                            782,584         476,802          2,808 
 Trade and other receivables          3,113,770         221,981        194,897 
 Corporation tax receivable                   -         178,302              - 
 Cash and cash equivalents            2,214,496       1,351,746        465,671 
--------------------------------  -------------  --------------  ------------- 
 Total current assets                 6,110,850       2,228,831        663,376 
--------------------------------  -------------  --------------  ------------- 
 
 Total assets                         6,766,013       3,041,087      1,335,453 
--------------------------------  -------------  --------------  ------------- 
 
 Current liabilities 
 Trade and other payables             2,994,003         312,516        383,186 
 Deferred tax liability                       -               -         87,379 
 Lease Liabilities                            -               -          4,895 
 Provisions                             226,250               -        226,250 
 Total current liabilities            3,220,253         312,516        701,710 
--------------------------------  -------------  --------------  ------------- 
 
 Non-Current liabilities 
 Lease Liabilites                             -               -              - 
 Loans and borrowings                         .         102,697        104,367 
--------------------------------  -------------  --------------  ------------- 
 Total non-current liabilities                -         102,697        104,367 
--------------------------------  -------------  --------------  ------------- 
 
 Total liabilities                    3,220,253         415,213        806,077 
--------------------------------  -------------  --------------  ------------- 
 
 Net assets                           3,545,760       2,625,874        529,376 
--------------------------------  -------------  --------------  ------------- 
 
 Share capital                          725,246         489,822        517,822 
 Share premium account               15,512,921      12,179,653     12,441,832 
 Capital redemption reserve           1,814,674       1,814,674      1,814,674 
 Retained earnings                 (15,744,391)    (13,060,255)   (15,475,669) 
 Reverse acquisition reserve        (6,044,192)     (6,044,192)    (6,044,192) 
 Deferred shares                      6,358,720       6,358,720      6,358,720 
 Share-based payment reserve            922,782         887,452        916,189 
 Total equity                         3,545,760       2,625,874        529,376 
--------------------------------  -------------  --------------  ------------- 
 

The accompanying notes are an integral part of these financial statements.

Consolidated statement of changes in equity

For the 6 months ended 30 June 2021

 
                        Share        Share      Capital       Retained       Reverse   Share-based    Deferred         Total 
                      capital      Premium   redemption       earnings   acquisition       payment      Shares 
                                                reserve                                    reserve 
                                                                             reserve 
 
                          GBP          GBP          GBP            GBP           GBP           GBP         GBP           GBP 
---------------  ------------  -----------  -----------  -------------  ------------  ------------  ----------  ------------ 
 
 Equity as 
  at                6,623,667   10,739,816    1,814,674   (11,713,042)   (6,044,192)       812,899           -     2,233,822 
 01-Jan-20 
 Loss for 
  the year                  -            -            -    (3,762,627)             -             -           -   (3,762,627) 
---------------  ------------  -----------  -----------  -------------  ------------  ------------  ----------  ------------ 
 Total                      -            -            -    (3,762,627)             -             -           -   (3,762,627) 
 comprehensive 
  loss 
 Issue of 
  shares net 
  of expenses         252,875    1,702,016            -              -             -             -           -     1,954,891 
 Deferred 
  shares          (6,358,720)            -            -              -             -             -   6,358,720             - 
 Share-based 
  payments                  -            -            -              -             -       103,290           -       103,290 
---------------  ------------  -----------  -----------  -------------  ------------  ------------  ----------  ------------ 
 Equity as 
  at                  517,822   12,441,832    1,814,674   (15,475,669)   (6,044,192)       916,189   6,358,720       529,376 
                 ------------  -----------  -----------  -------------  ------------  ------------  ----------  ------------ 
 31-Dec-20 
---------------  ------------  -----------  -----------  -------------  ------------  ------------  ----------  ------------ 
 Loss for                   -            -            -              -             -             -           -             - 
  the period 
---------------  ------------  -----------  -----------  -------------  ------------  ------------  ----------  ------------ 
 Total 
  comprehensive 
  loss                      -            -            -      (268,722)             -             -           -     (268,722) 
 Issue of 
  shares net 
  of expenses         207,424    3,071,089            -              -             -             -           -     3,278,513 
 Deferred                   -            -            -              -             -             -           -             - 
  Shares 
 Share-based 
  payments                  -            -            -              -             -         6,593           -         6,593 
---------------  ------------  -----------  -----------  -------------  ------------  ------------              ------------ 
 Equity as 
  at                  725,246   15,512,921    1,814,674   (15,744,391)   (6,044,192)       922,782   6,358,720     3,545,760 
                 ------------  -----------  -----------  -------------  ------------  ------------  ----------  ------------ 
 30-Jun-21 
---------------  ------------  -----------  -----------  -------------  ------------  ------------  ----------  ------------ 
 

The accompanying notes are an integral part of these financial statements

Consolidated statement of cash flows

 
                                                                Unaudited      Unaudited            Audited 
                                                              6 months to    6 months to       12 months to 
                                                                  30 June        30 June 
                                                                     2021           2020   31 December 2020 
                                                                      GBP            GBP                GBP 
----------------------------------------------------------  -------------  -------------  ----------------- 
 Cash flows from operating activities 
   Loss before taxation                                         (268,722)    (1,348,882)        (3,762,627) 
 Adjustments for: 
   Depreciation and amortization                                   60,677        100,989            157,169 
   Impairment losses on intangible assets                               -              -            621,673 
   Finance expenses                                                 1,782          1,981              4,558 
   Share-based payments                                             6,593         74,553            103,291 
   Loss on sale of asset                                                -              -            179,718 
----------------------------------------------------------  -------------  -------------  ----------------- 
 Operating loss before working capital changes                  (199,670)    (1,171,359)        (2,696,218) 
 Changes in working capital 
   (Increase)/decrease in inventory                             (779,776)       (96,597)            380,205 
   (Increase) in trade and other receivables                  (2,918,873)       (99,216)           (72,132) 
   Increase in trade and other payables                         2,610,817         42,663            111,663 
   Decrease in lease liability                                    (4,895)              -          (281,888) 
   Increase in provisions                                               -              -            226,250 
----------------------------------------------------------  -------------  -------------  ----------------- 
 Cash used in operations                                      (1,292,397)    (1,324,509)        (2,332,120) 
   Tax received                                                         -              -            178,303 
   Interest paid on sale and leaseback                                  -          (718)                  - 
   Other interest paid                                            (1,782)        (1,262)            (1,193) 
 Net cash outflow from operating activities                   (1,294,179)    (1,326,489)        (2,155,010) 
----------------------------------------------------------  -------------  -------------  ----------------- 
 
 Investing activities 
   Purchase of property, plant and equipment                    (127,944)          (147)           (34,226) 
   Purchase of intangible assets                                  (3,198)        (2,709)            (2,777) 
   Sale of asset                                                        -        297,419            284,784 
  Acquisition of subsidiary in the year                                 -              -                109 
 Net cash flows used in investing activities                    (131,142)        294,563            247,890 
----------------------------------------------------------  -------------  -------------  ----------------- 
 
 Financing activities 
   Issue of ordinary shares (net of issue expenses)             3,278,513    (4,694,008)          1,655,528 
   Deferred Shares                                                      -      6,358,720                  - 
   Convertible Loan                                             (104,367)        102,697            101,000 
 Net cash flows from financing activities                       3,174,146      1,767,409          1,756,528 
----------------------------------------------------------  -------------  -------------  ----------------- 
 
 Net change in cash and cash equivalents                        1,748,825        735,483          (150,592) 
 Cash and cash equivalents at the beginning of the period         465,671        616,263            616,263 
----------------------------------------------------------  -------------  -------------  ----------------- 
 Cash and cash equivalents at the end of the period             2,214,496      1,351,746            465,671 
----------------------------------------------------------  -------------  -------------  ----------------- 
 
 

Notes to the unaudited interim financial information for the 6 months ended 30 June 2021

   1.    General information 

MyHealthChecked Plc (the "Company") is a public limited company incorporated and domiciled in England and Wales. The registered office of the Company is The Maltings, East Tyndall Street, Cardiff, CF24 5EA. The registered company number is 06573154.

The principal activity of the Company and its subsidiary is in the development and commercialisation of mobile health diagnostics medical devices.

   2.    Significant accounting policies 

Basis of preparation

The interim financial information for the six months ended 30 June 2021, which was approved by the Board of Directors on 28 September 2021, does not constitute statutory accounts as defined by section 434 of the Companies Act 2006.

These interim consolidated financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all disclosures that would otherwise be required in a complete set of financial statements.

The financial information presented is unaudited and has been prepared using the same accounting policies as those adopted in the financial statements for the year ended 31 December 2020 and expected to be adopted in the financial year ending 31 December 2021.

The interim financial information includes unaudited comparative figures for the unaudited 6 months to 30 June 2020 of Concepta Diagnostics Limited and comparatives for the year ended 31 December 2020 that have been extracted from the audited financial statements for that year.

The financial statements for the year ended 31 December 2020 were reported on by the Company's auditors and delivered to the Registrar of Companies. The report of the auditors was unqualified and did not contain an adverse statement under section 498 (2) or (3) of the Companies Act 2006.

In the opinion of the Directors, the interim financial information for the period presents fairly the financial position and the results from operations and cash flows for the period.

Going concern

The interim financial statements have been prepared under the going concern basis as the Directors have undertaken a review of the future financing requirements of the ongoing operation of the Group and considers the Group is able to meet its working capital requirements.

The Directors have prepared a cash flow forecast covering a period extending beyond 12 months from the date of these financial statements and including the impact of COVID-19.

The forecast contains certain assumptions about the performance of the business including growth in future revenue, the cost model and margins; and importantly the level of cash recovery from trading. The directors are aware of the risks and uncertainties facing the business but the assumptions used are the Directors' best estimate of the future development of the business.

After considering the forecasts and the risks, the Directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. For these reasons, they continue to adopt the going concern basis of accounting in preparing the annual financial statements. The financial statements do not include any adjustments that would result from the going concern basis of preparation being inappropriate.

   3.    Segment information 

The Group has one operating segment which is involved in the provision of diagnostic healthcare products. The revenue for this operating segment for the period to 30 June 2021 is as reported in the Consolidated statement of comprehensive income.

   4.    Loss per share 
 
                                                                        Unaudited       Unaudited             Audited 
                                                                      6 months to     6 months to        12 months to 
                                                                     30 June 2021    30 June 2020    31 December 2020 
 Basic and diluted 
 Loss for the period used in basic & diluted EPS (GBP)                  (268,722)     (1,348,882)         (3,762,627) 
 Weighted average number of shares used in basic and diluted EPS      664,508,816     343,591,481         420,756,606 
 Loss per share (pence)                                                    (0.04)          (0.39)              (0.89) 
-----------------------------------------------------------------  --------------  --------------  ------------------ 
 

Basic loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.

Due to the loss in the periods the effect of the share options was considered anti-dilutive and hence no diluted loss per share information has been provided.

   5.    Taxation 
 
                                     Unaudited       Unaudited             Audited 
                                   6 months to     6 months to        12 months to 
                                  30 June 2021    30 June 2020    31 December 2020 
                                           GBP             GBP                 GBP 
------------------------------  --------------  --------------  ------------------ 
 The tax credit is as follows: 
 UK Corporation tax 
 Tax credit - current period                 -               -                   - 
 Total current tax                           -               -                   - 
------------------------------  --------------  --------------  ------------------ 
 
 

The tax credit represents the research and development tax credit for current interim and prior periods.

   6.    Related Party Transactions 

Fees paid to directors and other companies for directors' services and reimbursement of expenses for the period to 30 June 20 21 were GBP240,483 (June 20 20 GBP180,786 : 31 December 20 20 : GBP 275,014 ) and GBP 1,748 (June

20 20 : GBP 4,719 December 20 20 :   GBP 9,071 ) were outstanding at period ended 30 June 20 21 . 

These interim financial statements will be notified in accordance with the AIM Rules for Companies, and will be available shortly on the Company's website at https://investors.myhealthchecked.com/.

   7.    Placing and funds raised 

On 22 February 2021, the Company raised GBP3,505,109 (before expenses) through a subscription of 207,424,361 new Ordinary Shares. 194,285,714 were issued at GBP0.0175 per Ordinary Share and 13,138,647 were issued from previously received loan stock at GBP0.008 per Ordinary Share.

The primary use of the net proceeds will be to invest in developing and extending the MyHealthChecked Plc portfolio through new product development. Additionally, there is a requirement to strengthen and develop the marketing effort, appointing core marketing personnel, and continuing to refine the direct-to-consumer activities, through retail launch and targeting strategic commercial contracts to exploit the MyHealthChecked Plc portfolio.

   8.    Events after the reporting period 

On 2 July 2021 the Company acquired 100% of the share capital of Nell Health Ltd ("Nell Health"), a provider of genetic testing and personalised nutrition consultancy services, for an initial consideration of GBP1.202m, comprising GBP1.152m payable in shares in the company's ultimate parent company, MyHealthChecked Plc and GBP0.05m in cash, with a deferred consideration of up to GBP1.0m payable in further shares in MyHealthChecked Plc, linked to performance milestones. Nell Health trading activity will be integrated within the MyHealthChecked Plc group and accounted as hived up during the 2021 financial year.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IR QVLFLFKLXBBF

(END) Dow Jones Newswires

September 29, 2021 02:00 ET (06:00 GMT)

Concepta (LSE:CPT)
Gráfica de Acción Histórica
De Nov 2021 a Dic 2021 Haga Click aquí para más Gráficas Concepta.
Concepta (LSE:CPT)
Gráfica de Acción Histórica
De Dic 2020 a Dic 2021 Haga Click aquí para más Gráficas Concepta.